The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
New Drugs for Rheumatoid Arthritis
Abstract
Rheumatoid arthritis affects about 1 percent of the U.S. population and can cause irreversible joint deformities and functional impairment. Although the cause of this autoimmune disease remains obscure, greater understanding of its underlying mechanisms has facilitated the development of new drugs and revolutionized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., & Kollias, G. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04978.x · Cited by 1,660
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Kindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254
The Tumor Necrosis Factor Ligand and Receptor Families
Bazzoni, F., & Beutler, B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342607 · Cited by 1,225
Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10524 · Cited by 1,214
Guidelines for the management of rheumatoid arthritis: 2002 Update
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) · Arthritis & Rheumatism · doi:10.1002/art.10148 · Cited by 1,185
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Guidelines for the management of rheumatoid arthritis: 2002 Update
Yood, R. A. (2002) · Cited by 1,090
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams, R. O., Feldmann, M., & Maini, R. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9784 · Cited by 989
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins
Smith, C. A., Davis, T., Anderson, D., Solam, L., Beckmann, M. P., Jerzy, R., Dower, S. K., Cosman, D., & Goodwin, R. G. (1990) · Science · doi:10.1126/science.2160731 · Cited by 959
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 754
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 749
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10679 · Cited by 655
Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, J. A., & Woody, J. N. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90632-7 · Cited by 640
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
Chu, C. Q., Field, M., Feldmann, M., & Maini, R. N. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340908 · Cited by 578
Saxne, T., Palladino, M. A., Heinegãrd, D., Talal, N., & Wollheim, F. A. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310816 · Cited by 566
Mohan, V. P., Scanga, C. A., Yu, K., Scott, H. M., Tanaka, K. E., Tsang, E., Tsai, M. C., Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1847-1855.2001 · Cited by 536
Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Leflunomide: mode of action in the treatment of rheumatoid arthritis
Breedveld, F. C., & Dayer, J.-M. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.11.841 · Cited by 485
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Shakoor, N., Michalska, M., Harris, C. A., & Block, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07714-0 · Cited by 458
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
St.Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 417
Taylor, P. C., Peters, A. M., Paleolog, E., Chapman, P. T., Elliott, M. J., McCloskey, R., Feldmann, M., & Maini, R. N. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<38::aid-anr6>3.0.co;2-l · Cited by 405
Jiang, Y., Genant, H. K., Watt, I., Cobby, M., Bresnihan, B., Aitchison, R., & McCabe, D. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1001::aid-anr7>3.0.co;2-p · Cited by 399
Baecklund, E., Ekbom, A., Sparén, P., Feltelius, N., & Klareskog, L. (1998) · BMJ · doi:10.1136/bmj.317.7152.180 · Cited by 394
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Bozkurt, B., Torre-Amione, G., Warren, M. S., Whitmore, J., Soran, O. Z., Feldman, A. M., & Mann, D. L. (2001) · Circulation · doi:10.1161/01.cir.103.8.1044 · Cited by 388
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., Luggen, M. E., Keystone, E., Weisman, M. H., Bensen, W. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-9-200211050-00007 · Cited by 353
Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy
(2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441415 · Cited by 330
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
Mladenovic, V., Domljan, Z., Rozman, B., Jajic, I., Mihajlovic, D., Dordevic, J., Popovic, M., Dimitrijevic, M., Zivkovic, M., Campion, G., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381111 · Cited by 303
Etanercept therapy in children with treatment-resistant uveitis
Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., Gallagher, K., & Stout, T. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1411::aid-art235>3.0.co;2-o · Cited by 298
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S., Lovy, M., DeVries, T., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284
Sharp, J. T., Strand, V., Leung, H., Hurley, F., & Loew-Friedrich, I. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200003)43:3<495::aid-anr4>3.0.co;2-u · Cited by 278
Ekström, K., Hjalgrim, H., Brandt, L., Baecklund, E., Klareskog, L., Ekbom, A., & Askling, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10939 · Cited by 267
Clinical Pharmacokinetics of Leflunomide
Rozman, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00003 · Cited by 250
Campion, G. V., Lebsack, M. E., Lookabaugh, J., & Gordon, G. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390704 · Cited by 247
Stone, J. H., Uhlfelder, M. L., Hellmann, D. B., Crook, S., Bedocs, N.-M., & Hoffman, G. S. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200105)44:5<1149::aid-anr197>3.0.co;2-f · Cited by 244
Nuki, G., Bresnihan, B., Bear, M. B., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10578 · Cited by 222
Synovial interleukin‐1 receptor antagonist and interleukin‐1 balance in rheumatoid arthritis
Firestein, G. S., Boyle, D. L., Yu, C., Paine, M. M., Whisenand, T. D., Zvaifler, N. J., & Arend, W. P. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370507 · Cited by 210
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
Moreland, L. W., Cohen, S., Baumgartner, S. W., et al. (2001) · PubMed · Cited by 201
Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9%3c1564::aid-art6%3e3.0.co;2-m · Cited by 197
den Broeder, A. A., van de Putte, L., Rau, R., Schattenkirchner, M., van Riel, P. L. C. M., Sander, O., Binder, C., Fenner, H., Bankmann, Y., Velagapudi, R. B., et al. (2002) · PubMed · Cited by 195
Manna, S. K., Mukhopadhyay, A., & Aggarwal, B. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5962 · Cited by 186
Siemasko, K., Chong, A. S.-F., Jäck, H.-M., Gong, H., Williams, J. W., & Finnegan, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1581 · Cited by 174
The Pharmacokinetics of Etanercept in Healthy Volunteers
Korth-Bradley, J. M., Rubin, A. S., Hanna, R. K., et al. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19126 · Cited by 155
Fichtlscherer, S., Rössig, L., Breuer, S., Vasa‐Nicotera, M., Dimmeler, S., & Zeiher, A. M. (2001) · Circulation · doi:10.1161/hc5001.101749 · Cited by 146
Pharmacokinetics of anakinra in subjects with different levels of renal function
Yang, B., Baughman, S., & Sullivan, J. T. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00094-8 · Cited by 145
Adverse reactions to TNF-α inhibitors in rheumatoid arthritis
Day, R. O. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07718-8 · Cited by 131
Rozman, B., Praprotnik, S., Logar, D., Tomšič, M., Hojnik, M., Kos-Golja, M., Accetto, R., & Dolenc, P. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.567 · Cited by 114
Lee, H., Kimko, H. C., Rogge, M. C., Wang, D., Nestorov, I. A., & Peck, C. C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17635-1 · Cited by 110
Reactivation of histoplasmosis after treatment with infliximab
Nakelchik, M., & Mangino, J. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00945-7 · Cited by 108
Etanercept and infliximab associated with cutaneous vasculitis
McCain, M. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.1.116 · Cited by 99
Newton, R. C., Solomon, K. A., Covington, M. B., Decicco, C. P., Haley, P. J., Friedman, S., & Vaddi, K. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.90003.iii25 · Cited by 97
Kremer, J. M. (1999) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(99)80034-1 · Cited by 93
Neidel, J., Schulze, M., & Lindschau, J. (1995) · Inflammation Research · doi:10.1007/bf01782262 · Cited by 88
Fleischmann, R., Baumgartner, S. W., Tindall, E. A., Weaver, A. L., Moreland, L. W., Schiff, M. H., Martin, R. W., & Spencer-Green, G. (2003) · PubMed · Cited by 86
Listeria Meningitis After Treatment With Infliximab
Kamath, B. M., Mamula, P., Baldassano, R. N., et al. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200204000-00018 · Cited by 86
Drug-induced systemic lupus erythematosus and TNF-α blockers
MOHAN, A. K., Edwards, E. T., Coté, T. R., Siegel, J. N., & Braun, M. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09800-8 · Cited by 82
In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide
Xu, X., Shen, J., Mall, J. W., Myers, J. A., Huang, W., Blinder, L., Saclarides, T. J., Williams, J. W., & Chong, A. S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00228-2 · Cited by 76
Leflunomide can potentiate the anticoagulant effect of warfarin
Lim, V., & Pande, I. (2002) · BMJ · doi:10.1136/bmj.325.7376.1333 · Cited by 37
Marchesoni, A., Arreghini, M., Panni, B., Battafarano, N., & Uziel, L. D. (2002) · Lara D. Veeken · doi:10.1093/rheumatology/key051 · Cited by 34
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Shigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Metadata
- Authors
- Olsen, N. J., & Stein, C. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-05-20
- Volume
- 350
- Issue
- 21
- Pages
- 2167-2179
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2031092466
- Cited by
- 626
- References
- 94
- FWCI
- 42.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.